Abstract 1766
Background
Despite the availability of improved treatment options in BRAFV600 mutation-positive metastatic melanoma, key questions regarding therapy sequence and duration, tumor dynamics, as well as efficacy in patient subgroups (e.g. brain metastases, concomitant diseases) that were not included in previous phase III clinical trials remain unresolved. Therefore, the objective of this non-interventional prospective study (COMBI-r) was to assess the treatment of a broad patient population in metastatic melanoma with dabrafenib and trametinib in clinical routine.
Methods
Between December 2015 and December 2018, 504 patients at 58 German Skin Cancer Centers were enrolled in COMBI-r. This interims analysis focuses on efficacy (OS, PFS, ORR, DOR) and safety of dabrafenib and trametinib in patients treated for at least 1 year or who have already terminated treatment (approx. 330 patients). During the first year on treatment, visits were scheduled every 3 months, followed by half-yearly visits until end of treatment (EoT), and two follow-up visits at 3 and 6 months.
Results
Efficacy outcomes will be correlated with patient demographics at baseline as well as clinical, laboratory and biological parameters. In addition, patients will be assigned to slow, intermediate and fast tumor dynamic subgroups based on key baseline characteristics previously shown predictive of clinical benefit including tumor stage, organ involvement, therapy line and laboratory markers (S100, LDH).
Conclusions
Data from the COMBI-r interims analysis can provide insights as to whether efficacy and safety demonstrated in clinical trials as well as currently acknowledged predictive factors for clinical benefit and long-term outcomes are transferable to clinical routine. Further, it remains to be evaluated whether other criteria such as tumor dynamics are potentially suitable to predict outcomes in broader and more heterogeneous patient populations in metastatic melanoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis Pharma GmbH.
Funding
Novartis Pharma GmbH.
Disclosure
C. Berking: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Amgen; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : BMS; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Merck Serono; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Novartis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : 4SC; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, personal fees and non-financial support : Pierre Fabre; Honoraria (self), Non-remunerated activity/ies, personal fees and non-financial support : Sanofi-Aventis; Honoraria (self), Non-remunerated activity/ies, institutional grants : Array Pharma; Honoraria (self), Non-remunerated activity/ies, institutional grants : Regeneron; Honoraria (self), Non-remunerated activity/ies, institutional grant and personal fees (member of steering committee) related to the submitted work: Novartis. E. Livingstone: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Actelion; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Medac; Travel / Accommodation / Expenses: Pierre Fabre. M. Weichenthal: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Sun Pharma. K. Wittmann: Full / Part-time employment: Novartis. T. Eigentler: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Advisory / Consultancy: Leo Pharma; Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: MSD. P. Mohr: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: GSK; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre. F. Kiecker: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre. C. Loquai: Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Sun Pharma. D. Debus: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi. R. Gutzmer: Research grant / Funding (self): Pfizer; Research grant / Funding (self): Johnson&Johnson; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Amgen; Advisory / Consultancy, Research grant / Funding (self): MerckSerono; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: GSK; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy: Almirall-Hermal; Honoraria (self), Advisory / Consultancy: LEO; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self): 4SC; Advisory / Consultancy: Incyte; Advisory / Consultancy: SUN; Honoraria (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1291 - PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy
Presenter: Yun Fan
Session: Poster Display session 3
Resources:
Abstract
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract